source
- Capricor Therapeutics sees stock surge as FDA signals openness to extend review of DMD cell therapyCapricor Therapeutics' CEO Linda Marbán told investors that the FDA is receptive to adding open label extension data to its Biologics License Application for deramiocel, its Duchenne muscular dystr…
- New state and federal funding fuels biotech hub growth in Pennsylvania, Kansas City and beyondGovernment programs in Pennsylvania, New York, Kansas City and Central Virginia are pouring new funding into regional biotech hubs as pharma manufacturing investment surges. Matt Gardner, sector p…